A quick check through the company board of directors and management teams shows a lot of former experience with biotech acquisitions particularly with the CEO and Chairman. Is that the end game here? Have Mela Sciences acquired? If so for how much?
Great stuff all around. Eravacycline on track for NDA this year with Blockbuster potential. 2 new INDs this year. Company has cash to run through end of 2016. I really don't see how Tetraphase doesn't get acquired. These guys are flying under the radar at the moment with such a small market cap.